---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-022093"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2021-09-07T23:59:59+00:00"
generated_at: "2026-06-29T05:38:20.481578+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Provectus reports fully diluted shares of 528.7M as of Sep 7, 2021, down from 563.9M in 2017

## Summary
- Fully diluted shares outstanding as of Sep 7, 2021: 528,667,356 vs 563,911,848 in 2017.
- Common shares outstanding: 416,575,669; warrants: 512,500; options: 4,800,000; Series D/D-1 conversion shares: 106,779,187.
- All Private Warrants expired by Oct 31, 2020; Listed Warrants expired Jun 23, 2020.
- Convertible notes ($30.56M) converted into Series D/D-1 Preferred on Jun 20, 2021, convertible into ~106.8M common shares.
- Remaining Series B Preferred converted Aug 25, 2021; 13.35M Ratchet Warrants exercised, 68.7M expired by Aug 30, 2021.

## SEC filing metadata
- accession: 0001493152-21-022093
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2021-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315221022093/0001493152-21-022093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315221022093/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-022093
- JSON: https://secwatch.observer/filing/0001493152-21-022093.json
- Plain text: https://secwatch.observer/filing/0001493152-21-022093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.